Literature DB >> 24641151

Treatment and prevention of Mycobacterium ulcerans infection (Buruli ulcer) in Australia: guideline update.

Daniel P O'Brien1, Grant Jenkin2, John Buntine3, Christina M Steffen4, Anthony McDonald5, Simon Horne6, N Deborah Friedman5, Eugene Athan5, Andrew Hughes5, Peter P Callan7, Paul D R Johnson8.   

Abstract

• Guidelines reflecting contemporary clinical practice in the management of Buruli ulcer (Mycobacterium ulcerans infection) in Australia were published in 2007. • Management has continued to evolve, as new evidence has become available from randomised trials, case series and increasing clinical experience with oral antibiotic therapy. • Therefore, guidelines on the diagnosis, treatment and prevention of Buruli ulcer in Australia have been updated. They include guidance on the new role of antibiotics as first-line therapy; the shortened duration of antibiotic treatment and the use of all-oral antibiotic regimens; the continued importance, timing and role of surgery; the recognition and management of paradoxical reactions during antibiotic treatment; and updates on the prevention of disease.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24641151     DOI: 10.5694/mja13.11331

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  14 in total

Review 1.  Antimycobacterial Susceptibility Testing of Nontuberculous Mycobacteria.

Authors:  Barbara A Brown-Elliott; Gail L Woods
Journal:  J Clin Microbiol       Date:  2019-09-24       Impact factor: 5.948

2.  Risk Factors Associated with Antibiotic Treatment Failure of Buruli Ulcer.

Authors:  Daniel P O'Brien; N Deborah Friedman; Aaron Walton; Andrew Hughes; Eugene Athan
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

Review 3.  Buruli Ulcer, a Prototype for Ecosystem-Related Infection, Caused by Mycobacterium ulcerans.

Authors:  Dezemon Zingue; Amar Bouam; Roger B D Tian; Michel Drancourt
Journal:  Clin Microbiol Rev       Date:  2017-12-13       Impact factor: 26.132

4.  Increasing Experience with Primary Oral Medical Therapy for Mycobacterium ulcerans Disease in an Australian Cohort.

Authors:  N Deborah Friedman; Eugene Athan; Aaron L Walton; Daniel P O'Brien
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

5.  Mycobacterium ulcerans treatment--can antibiotic duration be reduced in selected patients?

Authors:  Raquel Cowan; Eugene Athan; N Deborah Friedman; Andrew J Hughes; Anthony McDonald; Peter Callan; Janet Fyfe; Daniel P O'Brien
Journal:  PLoS Negl Trop Dis       Date:  2015-02-06

6.  Clinical Epidemiology of Buruli Ulcer from Benin (2005-2013): Effect of Time-Delay to Diagnosis on Clinical Forms and Severe Phenotypes.

Authors:  Carlos Capela; Ghislain E Sopoh; Jean G Houezo; René Fiodessihoué; Ange D Dossou; Patrício Costa; Alexandra G Fraga; João F Menino; Rita Silva-Gomes; Edgard M Ouendo; Fernando Rodrigues; Jorge Pedrosa
Journal:  PLoS Negl Trop Dis       Date:  2015-09-10

7.  Pre-emptive steroids for a severe oedematous Buruli ulcer lesion: a case report.

Authors:  Daniel P O'Brien; Sarah Huffam
Journal:  J Med Case Rep       Date:  2015-05-01

8.  Mycobacterium ulcerans in the Elderly: More Severe Disease and Suboptimal Outcomes.

Authors:  Daniel P O'Brien; N Deborah Friedman; Raquel Cowan; James Pollard; Anthony McDonald; Peter Callan; Andrew Hughes; Eugene Athan
Journal:  PLoS Negl Trop Dis       Date:  2015-12-02

9.  Clinical features and management of a severe paradoxical reaction associated with combined treatment of Buruli ulcer and HIV co-infection.

Authors:  Franck Wanda; Patrick Nkemenang; Genevieve Ehounou; Marie Tchaton; Eric Comte; Laurence Toutous Trellu; Isabelle Masouyé; Vanessa Christinet; Daniel P O'Brien
Journal:  BMC Infect Dis       Date:  2014-07-30       Impact factor: 3.090

10.  Increased Severity and Spread of Mycobacterium ulcerans, Southeastern Australia.

Authors:  Alex Y C Tai; Eugene Athan; N Deborah Friedman; Andrew Hughes; Aaron Walton; Daniel P O'Brien
Journal:  Emerg Infect Dis       Date:  2018-01-17       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.